Introduction
============

Medulloblastoma (MB) is one of the most common intracranial malignant tumors in children. Standardized treatment options including maximal surgical resection, radiation therapy, and chemotherapy can improve overall five-year survival rates; however, the prognosis of patients with advanced disease is still unsatisfactory ([@ref-15]). Despite extensive studies on the pathogenesis and progression of MB, the pathophysiology of disease development is still unclear. The pathogenesis of MB is closely related to many factors such as mutations in genes, abnormalities in cellular immunity, and changes in environmental factors ([@ref-29]). A deep understanding of the changes in protein expression involved in the pathogenesis of MB is critical for the development of better treatment strategies.

Gene chip is a genetic testing technology that has been in use for more than a decade. The gene chip technology can rapidly detect changes in gene expression in the sample and is suitable for screening differentially expressed genes (DEGs) ([@ref-28]). In recent years, gene chip technology has been widely used, and data from numerous microarray studies have been stored in free public databases. These databases provide valuable data for further research. So far, several gene chip data have been analyzed, and hundreds of different genes involved in the development of several central nervous system cancers such as gliomas have been identified ([@ref-32]; [@ref-36]). However, most gene chip data is a mixture of both MB and glioma and does not accurately represent changes in MB, and therefore does not generate satisfactory results. There have been reports of microarray data to find DEGs in medulloblastoma ([@ref-25]). However, the reliability of the analysis results was controversial due to the heterogeneity of the sample from a single cohort study. Therefore, most single-chip analyses are not sufficient to identify effective biomarkers in MB. To overcome this, we used data derived from four gene chips to identify effective biomarkers for MB. This method is more accurate and does not have the disadvantages associated with the single-chip analysis.

In this study, we downloaded four MB microarray datasets ([GSE42656](GSE42656), [GSE74195](GSE74195), [GSE109401](GSE109401), and [GSE50161](GSE50161)) from free public Gene Expression Omnibus database (GEO). A total of 77 MB samples and 39 normal brain samples were included in this study. We identified the DEGs using the Limma package in R software (version 3.5.0) from the four gene expression profiles and subsequently, used the Venny online tool for further integrated analyses. We then employed the DAVID databases and Kobas online tool to identify the functions of the identified DEGs and the key cell signaling pathways involved. The network of protein-protein interaction (PPI) was generated using the STRING database. Finally, we used the CMap database to explore potential small-molecule compounds that can be used for treating MB.

Materials & Methods
===================

Microarray data information
---------------------------

We downloaded the gene expression profile data for [GSE42656](GSE42656), [GSE74195](GSE74195), [GSE109401](GSE109401), and [GSE50161](GSE50161) from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>). The [GSE42656](GSE42656) data set was based on the [GPL6947](GPL6947) Platforms (Illumina HumanHT−12 V3.0 expression beadchip) and contained nine MB samples and 16 normal brain samples ([@ref-9]). The [GSE74195](GSE74195) data set was based on the [GPL570](GPL570) Platform (Affymetrix Human Genome U133 Plus 2.0 Array) and contained 27 MB and five normal brain tissue samples ([@ref-4]). The [GSE50161](GSE50161) data set was based on the [GPL570](GPL570) Platform (Affymetrix Human Genome U133 Plus 2.0 Array) and included 22 MB samples and 13 normal brain tissues ([@ref-8]). The [GSE109401](GSE109401) data set was based on [GPL16686](GPL16686) Platforms (Affymetrix Human Gene 2.0 ST Array (transcript (gene) version)) and included 19 medulloblastoma samples and five normal brain samples ([@ref-23]). We selected these four gene expression profiles for further integrated analyses to avoid racial differences and errors in individual experiments.

Identification of DEGs in medulloblastoma
-----------------------------------------

The DEGs were identified based on the series matrix file using Limma package in R software (version 3.5.0) according to the cut-off standard (*p* \< 0.05 and logFC \>1) ([@ref-6]). The four sets of differential expression data were respectively divided into upregulated DEmRNAs and downregulated DEmRNAs and were uploaded to Venny (<http://bioinfogp.cnb.csic.es/tools/venny/>) for integrated analyses. A heat map was generated using the pheatmap package in R. The [GSE74195](GSE74195) dataset was used as the reference to generate the heat map. The heatmap showed 29 upregulated DEGs, and 75 downregulated DEGs.

GO and KEGG enrichment analysis of DEGs
---------------------------------------

The DAVID online database and Kobas online tool were used for functional and pathway enrichment analyses ([@ref-11]). We uploaded the DEGs to DAVID for GO functional annotation analysis and Kobas for KEGG pathway enrichment analysis. *P* \< 0.05 was used as the cut-off value.

Building a PPI network
----------------------

The STRING public database, which provides PPI network analysis, can evaluate direct and indirect links between DEGs (<https://string-db.org>) ([@ref-7]). The DEGs were uploaded to STRING to obtain the PPI network using an Interaction score of 0.2. Cytoscape was used for visualizing the PPI network and for identifying the hub genes based on the degree of connectivity between DEGs.

Identification of small-molecule compounds for the treatment of MB
------------------------------------------------------------------

CMap, an online tool, can be based on the gene expression profile of a disease to mine potential therapeutic drugs ([@ref-16]). We divided the DEGs of MB into upregulated DEGs and downregulated DEGs, and uploaded them to CMap to explore the drugs. *P* \< 0.001 and Enrichment \<-0.8 was used as the cut-off criteria. The 3D structures of the small-molecule compounds are available from PubChem (<https://pubchem.ncbi.nlm.nih.gov/>).

RNA isolation and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis
-------------------------------------------------------------------------------------------------

Total RNA is extracted from in normal human brain tissue and medulloblastoma cell lines (Daoy and D283) using Tri-Reagent (Sigma, USA) according to the manufacturer's instructions. NanoDrop One spectrophotometer (Thermo Fisher Scientific, USA) was used to evaluate the quality and quantity of the RNA. The Transcriptor First Stand cDNA Synthesis Kit (Roche, USA) was used to reverse transcribe total RNA into cDNA.The FastStart Universal SYBR Green Master (ROX) (Roche, Germany) and the QuantStudio software (Thermo Fisher Scientific, USA) were reserved for RT-qPCR based on the manufacturer 's instructions.The GAPDH gene was used as an endogenous reference.

The primer sequences were as follows: 5′-GGACACGTGCTCAGAGATT-3′ (sense) and 5′-TCTACGATGAGCTGTTTGTCTTC-3′ (antisense) for SYN1, 5′-GGGGTGATGTTGCCCTGTAA-3′ (sense) and 5′-AGGTCTGAGGCATTGGTTCG-3′(antisense) for CNTN2, 5′-CTGATTCTCCTGACCGTCTTTAC-3′ (sense) and 5′-GAACTTGGTCTGGAAGCTGAA-3′(antisense) for FAIM2,5 ′-CAAGTGCGAGGGATGCAAAT-3′ (sense) and 5′-TGGCACACTTCTCACACTCC-3′(antisense) for MT3, 5′-CTCAGCCTAGAAGGGAATATCAAC-3′ (sense) and 5′-CAGCAGGGCTGATCCATTT-3′(antisense) for SH3GL2, and 5′-CACCCACTCCTCCACCTTTGA-3′ (sense) and 5′-ACCACCCTGTTGCTGTAGCCA-3′ (anti- sense) for GAPDH. The results were analyzed using the - ΔCT method with an unpaired *t*-test, and a *P*-value \< 0.05 was considered a meaningful result.

Results
=======

Screening of DEGs in MB
-----------------------

We downloaded the gene expression datasets---[GSE42656](GSE42656), [GSE109401](GSE109401), [GSE50161](GSE50161), and [GSE74195](GSE74195) from GEO. From the [GSE42656](GSE42656) dataset, we identified 869 DEGs, of which 222 were upregulated, and 647 were downregulated. A total of 764 DEGs were identified from the [GSE109401](GSE109401) data set---274 upregulated and 490 downregulated; 5,494 DEGs from [GSE50161](GSE50161)---2,798 upregulated and 2,696 downregulated, and 1,000 DEGs were identified from [GSE74195](GSE74195)---422 upregulated and 578 downregulated. Integrated analyses revealed that 104 DEGs were consistently expressed in the four data sets ([Figs. 1A](#fig-1){ref-type="fig"} and [1B](#fig-1){ref-type="fig"}); these included 29 upregulated DEGs, and 75 downregulated DEGs in MB tissue compared to the normal brain tissue ([Table 1](#table-1){ref-type="table"}). A heat map of the DEG distribution was generated using the [GSE74195](GSE74195) dataset as a reference ([Fig. S1](#supp-1){ref-type="supplementary-material"}).

![Using the Venny map to obtain common DEGs in MB, and the cross areas represented the commonly DEGs of the four datasets ([GSE42656](GSE42656), [GSE109401](GSE109401), [GSE50161](GSE50161), and [GSE74195](GSE74195)).\
(A) Commonly up-regulated genes (29 DEGs); (B) Commonly down-regulated genes (75 DEGs).](peerj-08-8670-g001){#fig-1}
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###### The 104 differentially expressed genes (DEGs), including 29 upregulated genes and 75 downregulated genes were identified in the medulloblastoma tissues from four profile datasets using normal brain tissues as a reference.

![](peerj-08-8670-g007)

  **DEGs**            **Gene name**
  ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Up-regulated 29     ACTL6A, UBE2C, TMEM97GTF2IRD1, INSM2, CDC20, PRC1, ZNF423, HMGB2, ODC1, MCM7, KLHDC8A, SOX11, RAD51AP1, KIF15, CDK6, EBF3, EYA2, TYMS, TTK, CD24, DACH1, SOX4, NUSAP1, RPGRIP1, KIF11, NEUROG1, OTX2, TOP2A
  Down-regulated 75   CADPS2, TMEM163, UNC13C, DNER, CNTNAP1, DNM3, TMOD1, FEZ1, RAPGEF4, RIT2, NDRG4, TPPP, TMEM55A, MT3, FAIM2, ABLIM1, RCAN2, MAP1A, DHCR24, NRXN2, PTGDS, CDS1, RASGRP1, PCP4, NRIP3, HPCAL4, PTCHD1, GAS7, KIAA0513, PMP2, PHACTR3, TF, CADM2, CNTN2, VSNL1, BCAS1, DKK3, SCRN1, FBXL16, ELOVL4, OPCML, DNM1, EEF1A2, TTC9B, CA11, CEND1, MOBP, SH3GL2, SCG5, EPDR1, LRRC3B, COX7A1, NAP1L3, TSPAN7, CAMK2B, OPTN, STMN4, CLSTN3, PEA15, SYN1, RNF175, REEP2, CSRP1, SYT11, TCEAL2, GPM6B, TPRG1L, ASTN1, MAP7D2, SIRPA, OLIG1, SYNGR3, ELMO1, HK1, VAMP2

**Notes.**

AbbreviationDEGsdifferentially expressed genes

Gene Ontology Analysis of DEGs
------------------------------

The identified DEGs were analyzed using DAVID using *p* \< 0.05 as the cut-off standard to identify the functions associated with the DEGs. The GO function annotation is divided into three functional groups---cell component (CC), molecular function (MF), and biological process (BP). As shown in [Fig. 2](#fig-2){ref-type="fig"} and [Table 2](#table-2){ref-type="table"}, within the BPs the upregulated DEGs were closely related to mitotic cell cycle, cell cycle phase-M phase, cell cycle process, cell cycle, spindle organization, and microtubule-based process and the downregulated DEGs were closely related to vesicle-mediated transport. Within CC the upregulated DEGs were closely related to the spindle-microtubule, and cytoskeleton, whereas the downregulated DEGs were closely related to the synapse, synapse part, clathrin-coated vesicle, synaptic vesicle, cytoplasmic vesicle, coated vesicle, cytoplasmic membrane-bounded vesicle, vesicle, and membrane-bounded vesicle. Within MF, the upregulated DEGs showed a close relationship with DNA binding and the downregulated DEGs did not show any association.

![Gene Ontology (GO) functional annotation analysis and significant terms of DEGs in MB and GO analysis divided into three parts.\
Cyan for cell component, pink for molecular function, and blue for biological process.](peerj-08-8670-g002){#fig-2}
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###### DEGs divided into upregulated genes and downregulated genes and their first ten meaningful GO enrichment analyses.

![](peerj-08-8670-g008)

  Term             Description                            Count   *P*-Value
  ---------------- -------------------------------------- ------- -------------
  Up-regulated                                                    
  GO:0005819       Spindle                                6       1.92E--06
  GO:0000278       Mitotic cell cycle                     8       5.99E--06
  GO:0003677       DNA binding                            15      1.12E--05
  GO:0022403       Cell cycle phase                       8       1.25E--05
  GO:0000279       M phase                                7       3.80E--05
  GO:0022402       Cell cycle process                     8       9.14E--05
  GO:0007049       Cell cycle                             9       9.45E--05
  GO:0007051       Spindle organization                   4       9.51E--05
  GO:0015630       Microtubule cytoskeleton               7       1.03E--04
  GO:0007017       Microtubule-based process              6       1.27E--04
  Down-regulated                                                  
  GO:0045202       Synapse                                11      5.27E--06
  GO:0016192       Vesicle-mediated transport             11      5.69E--05
  GO:0044456       Synapse part                           8       1.45E--04
  GO:0030136       Clathrin-coated vesicle                6       3.77E--04
  GO:0008021       Synaptic vesicle                       5       4.37E--04
  GO:0031410       Cytoplasmic vesicle                    11      7.37E--04
  GO:0030135       Coated vesicle                         6       8.80E--04
  GO:0016023       Cytoplasmic membrane-bounded vesicle   10      9.86E--04
  GO:0031982       Vesicle                                11      0.001022664
  GO:0031988       Membrane-bounded vesicle               10      0.001235649

**Notes.**

AbbreviationGOGene OntologyDEGsdifferentially expressed genes

![Kyoto Encyclopedia of Genes and Genomes (KEGG) signal pathway analysis of DEGs in MB.\
Red represent the common up-regulated genes and green represent the common down-regulated genes.](peerj-08-8670-g003){#fig-3}

KEGG pathway analysis
---------------------

The 104 DEGs were grouped as upregulated and downregulated DEGs and the cellular signaling pathways represented were analyzed by KEGG ([Fig. 3](#fig-3){ref-type="fig"} and [Table 3](#table-3){ref-type="table"}). The upregulated genes are mainly involved in the cell cycle, ubiquitin-mediated proteolysis, viral carcinogenesis, one-carbon pool by folate, and microRNAs in cancer. The downregulated genes are mainly involved in the synaptic vesicle cycle, bacterial invasion of epithelial cells, insulin secretion, HIF-1 signaling pathway, phospholipase D signaling pathway, and cell adhesion molecules (CAMs).

PPI network generation and identification of the hub gene
---------------------------------------------------------

The interrelationships between the 104 DEGs were analyzed using STRING. We found that 100 of the 104 DEGs were related to each other and were visualized using Cytoscape --100 nodes and 776 edges are included in the network of PPI and the hub gene based on the degree of connectivity between genes were identified ([Fig. 4A](#fig-4){ref-type="fig"}). Among the hub genes, the most significant hub genes were *SYN1, CNTN2, FAIM2, MT3*, and *SH3GL2* ([Fig. 4B](#fig-4){ref-type="fig"}).

Potential therapeutic drugs for MB
----------------------------------

Of the 104 DEGs, only 85 were eventually converted to IDs from 22,214 probes in the Affymetrix platform. After that, we used CMap and identified six potential therapeutic drugs based on set criteria ([Table 4](#table-4){ref-type="table"}). A PubMed literature search revealed that two drugs---vorinostat and resveratrol --have been reported to have a therapeutic effect in MB. The other three drugs, trichostatin A, pyrvinium, and prochlorperazine, have been reported to have therapeutic effects in other cancers. The 3D structures of these potential therapeutic drugs are available from PubChem ([Fig. 5](#fig-5){ref-type="fig"}).

Experiments verify the five hub DEmRNAs in MB
---------------------------------------------

To verify the expression levels of the five hub genes in the PPI network, RT-qPCR was used to detect their expression levels in normal human brain tissue and medulloblastoma cell lines (Daoy and D283). The five hub genes in the PPI network, including SYN1,CNTN2, FAIM2, MT3, and SH3GL2, were all down-regulated DEGs in MB, and this result was confirmed by RT-qPCR ([Fig. 6](#fig-6){ref-type="fig"}). This shows that our analysis results were completely credible.

10.7717/peerj.8670/table-3

###### KEGG pathway analysis of upregulated and downregulated genes in MB.

![](peerj-08-8670-g009)

  Database         ID         Term                                                        Gene Count   *P*-Value     Gene names
  ---------------- ---------- ----------------------------------------------------------- ------------ ------------- ---------------------------
  Up-regulated                                                                                                       
  KEGG PATHWAY     hsa04110   Cell cycle                                                  4            2.28E--06     TTK, CDC20, MCM7, CDK6
  KEGG PATHWAY     hsa04120   Ubiquitin mediated proteolysis                              2            0.004624353   CDC20, UBE2C
  KEGG PATHWAY     hsa05203   Viral carcinogenesis                                        2            0.009970546   CDC20, CDK6
  KEGG PATHWAY     hsa00670   One carbon pool by folate                                   1            0.015198488   TYMS
  KEGG PATHWAY     hsa05206   MicroRNAs in cancer                                         2            0.020243092   CDK6, SOX4
  KEGG PATHWAY     hsa03030   DNA replication                                             1            0.026628344   MCM7
  KEGG PATHWAY     hsa03022   Basal transcription factors                                 1            0.033001239   GTF2IRD1
  KEGG PATHWAY     hsa00330   Arginine and proline metabolism                             1            0.03652431    ODC1
  KEGG PATHWAY     hsa00480   Glutathione metabolism                                      1            0.037930065   ODC1
  KEGG PATHWAY     hsa05223   Non-small cell lung cancer                                  1            0.040735637   CDK6
  Down-regulated                                                                                                     
  KEGG PATHWAY     hsa04721   Synaptic vesicle cycle                                      4            8.12E--06     DNM3, UNC13C, DNM1, VAMP2
  KEGG PATHWAY     hsa05100   Bacterial invasion of epithelial cells                      3            0.000492126   DNM3, DNM1, ELMO1
  KEGG PATHWAY     hsa04911   Insulin secretion                                           3            0.000627009   RAPGEF4, CAMK2B, VAMP2
  KEGG PATHWAY     hsa04066   HIF-1 signaling pathway                                     3            0.001075892   HK1, TF, CAMK2B
  KEGG PATHWAY     hsa04072   Phospholipase D signaling pathway                           3            0.002737401   DNM3, RAPGEF4, DNM1
  KEGG PATHWAY     hsa04514   Cell adhesion molecules (CAMs)                              3            0.002843803   NRXN2, CNTN2, CNTNAP1
  KEGG PATHWAY     hsa04961   Endocrine and other Factor-regulated calcium reabsorption   2            0.003884233   DNM3, DNM1
  KEGG PATHWAY     hsa00524   Butirosin and neomycin biosynthesis                         1            0.011244262   HK1
  KEGG PATHWAY     hsa04144   Endocytosis                                                 3            0.01354801    DNM3, DNM1, SH3GL2
  KEGG PATHWAY     hsa04070   Phosphatidylinositol signaling system                       2            0.0153706     CDS1, TMEM55A

**Notes.**

AbbreviationKEGGKyoto Encyclopedia of Genes and GenomesIDidentification

Discussion
==========

Although several studies have been carried out to understand the pathogenesis of MB, there is no effective strategy to reduce the incidence or mortality of MB. This may be because most studies till date have focused on a single genetic event contributing to MB pathogenesis. Therefore, in order to identify effective molecular markers, we used data derived from four cohorts profile datasets obtained from the GEO database ([GSE42656](GSE42656), [GSE74195](GSE74195), [GSE109401](GSE109401), [GSE50161](GSE50161)). Integrated analyses of the four data sets revelated 104 DEGs including 29 upregulated, and 75 downregulated DEGs. Enrichment of these genes identified certain cellular signaling pathways which may provide novel insights to the understanding of the pathogenesis of MB. We also used CMap, a drug development tool, and identified six potential drugs that can be used for the treatment of MB. To our knowledge, this is the first study to use integrated bioinformatical analysis for studying the pathogenesis of MB.

GO enrichment analysis showed that the upregulated DEGs were mainly involved in the spindle, cell cycle phase, M phase, cell cycle, spindle organization, microtubule cytoskeleton and the downregulated DEGs were mainly closely related to clathrin-coated vesicle, synaptic vesicle, and cytoplasmic vesicle. These results are consistent with previous literature reports that spindle defects play a vital role in the pathological process of MB ([@ref-1]). LCL161 an inhibitor of apoptosis proteins (IAP) combined with chemotherapy can slow MB cell proliferation by inducing G2/M phase arrest ([@ref-3]). Patupilone, a microtubule stabilizer, can reduce clonogenic survival and enhance the therapeutic efficacy of radiotherapy effect in MB ([@ref-20]). *α*-synuclein binds to cytoplasmic vesicles to change the surface morphology of in U251 glioblastoma cells ([@ref-5]). Synaptic vesicle protein 2A is a predictor of the efficacy of levetiracetam in glioma patients ([@ref-4]). The internalization of clathrin-coated vesicles can reduce the sensitivity of metabotropic receptors in C6 cells ([@ref-18]).

![The PPI network of DEGs.\
(A) One hundred DEGs were incorporated into the network consisted of 29 upregulated (red) and 71 downregulated (green) genes; (B) hub genes determined by the degree of connectivity between DEGs.](peerj-08-8670-g004){#fig-4}

KEGG pathway analysis demonstrated that the upregulated genes have significant enrichment in pathways including one-carbon pool by folate, microRNAs in cancer, DNA replication, and basal transcription factors. Previous studies have shown that these signaling pathways are mainly involved in the development of cancer. For example, the basal transcription factors such as oncogene Orthodenticle Homeobox 2, play an important role in cell migration and proliferation in MB ([@ref-31]). Folate receptor (Folr1) participates in the pathway network of the one-carbon pool by folate, which is related to clinical, pathological, neuroimaging features, and prognosis of MB patients ([@ref-17]). MicroRNA-31 inhibits DNA replication by targeting minichromosome maintenance complex component 2 (MCM2), which has a strong inhibitory effect on MB growth ([@ref-13]). The downregulated genes were mainly involved in HIF-1 signaling pathway, phospholipase D signaling pathway, and phosphatidylinositol signaling system. These signaling pathways are involved in the pathological process of cancer. For example, phosphatidylinositol signaling system, such as the phosphatidylinositol 3-kinase (PI3K) pathway is associated with reduced survival in patients and is one of the most common signaling pathway-related abnormality in gliomas ([@ref-27]). Phospholipase D signaling pathway specifically inhibits autophagic flux and decreases GBM cell viability ([@ref-2]). The hypoxia-inducible factor-1 signaling pathway is vital for the invasion and metastasis of glioma cells ([@ref-33]). Together, our results show that the cellular pathways of DEGs identified in this study are closely related to the development of cancer.

10.7717/peerj.8670/table-4

###### Six small-molecule compounds identified as potential drugs for MB treatment by CMap analysis.

![](peerj-08-8670-g010)

  Term               Enrichment   *P*-Value
  ------------------ ------------ -----------
  Vorinostat         −0.842       0
  Resveratrol        −0.827       0
  Trichostatin A     −0.568       0
  Pyrvinium          −0.727       0.00077
  Prochlorperazine   −0.475       0.00082
  0175029-0000       −0.718       0.00099

**Notes.**

AbbreviationCMapconnectivity map

![The 3D structures of five small-molecule compounds identified as potential drugs for MB treatment.\
(A) Vorinostat, (B) Resveratrol, (C) Trichostatin A, (D) Pyrvinium, and (E) Prochlorperazine.](peerj-08-8670-g005){#fig-5}

![The expression levels of the five hubgenes in the PP Inetwork were detected by RT-qPCR.\
These included (A) SYN1, (B) CNTN2, (C) FAIM2, (D) MT3, and (E) SH3GL2 (*P* \< 0.05).](peerj-08-8670-g006){#fig-6}

The PPI network of DEGs represents an overview of their functional relations. Most of the hub genes selected in this network have been reported to be closely related to the pathological process of cancers. For example, *SYN1*, one of the neuronal genes, is related to the formation and maintenance of synaptic contacts and the expression of REST. RCOR1 may cause deregulated expression of *SYN1*, which contributes to the maintenance of glioblastoma stem-like cells (GSC) ([@ref-35]). *CNTN2*, a cell adhesion protein, is a downstream protein of RACK1, which affects the growth and differentiation of glioma cells through the RTK/Ras/MAPK signaling pathway ([@ref-34]). *FAIM2* is an anti-apoptotic molecule that promotes tumor cell growth through Fas-mediated mechanisms. Knock-down of FAIM2 can significantly affect tumor cell proliferation in small-cell lung cancer ([@ref-14]). *MT3* is a tumor suppressor gene, and its expression is significantly reduced in AML samples. The overexpression of *MT3* can inhibit cell proliferation and promote tumor cell apoptosis in pediatric acute myeloid leukemia ([@ref-26]). *SH3GL2*, as a suppressor for tumors, and has reduced expression in glioma tissues promoting migration and infiltration of glioma cells by enhancing STAT3/MMP2 signaling ([@ref-38]). These five hub genes have important regulatory effects in the pathophysiology of cancers, but their role has not been reported in MB. These hub genes are potential targets for the treatment of MB.

CMap is an online tool that can be used to identify potential therapeutic drugs based on DEGs in various disease ([@ref-16]). In the current study, we identified six drugs using CMap analysis. Two of these drugs have been previously reported to have a therapeutic effect on MB. The combination of vorinostat and MLN8237 can significantly inhibit the proliferation of MB cells ([@ref-19]). Resveratrol inhibits the growth of cancer cells by regulating the Notch signaling pathway to promote apoptosis and differentiation of MB cells ([@ref-30]). Three drugs --trichostatin A, pyrvinium, and prochlorperazine --have not been reported for the treatment of MB; however, several studies have reported their treatment efficacies in other cancers. Prochlorperazine and trichostatin A were used for treating glioblastoma and pyrvinium for the treatment of ovarian cancer ([@ref-10]; [@ref-21]; [@ref-37]). Although the six small-molecule compounds

obtained have not been adequately studied in MB. CMap is an online tool that provides researchers with an index based on disease DEGs to search for potential therapeutic drugs. Recently, some traditional drugs have been found to have new therapeutic effects. The development of new uses of old drugs can more quickly understand the pharmacological properties of drugs, which will help their early application in clinical treatment. For example, atorvastatin is a well-known traditional lipid-lowering drug, but in recent years, it has been found to have obvious therapeutic effects on chronic subdural hematoma ([@ref-12]). Metformin is a traditional an anti-diabetic drug. In recent years, new therapeutic effects have been discovered in human diseases such as anti-tumor effects, neuroprotective effects, etc ([@ref-22]; [@ref-24]). So we have reason to speculate that the small-molecule drugs identified by CMap analysis may be potential drugs for the treatment of MB.

Conclusions
===========

In summary, most single data set analyses are limited by the small sample size, high experimental error, and lack of ethnic differences, and therefore cannot reliably identify the important genes and pathways involved in the pathogenesis of diseases. In this study, the above problems were well avoided by using multiple data sets and integrated analysis to improve the reliability and accuracy of the results. We identified 104 DEGs from four groups of gene expression profiling data of MB and analyzed them comprehensively. The hub genes identified by PPI network analysis include *SYN1, CNTN2, FAIM2, MT3, and SH3GL2*, which are involved in the pathogenesis of different cancers. We also identified several small-molecule compounds that may have potential therapeutic effects on MB. These findings provide new insights into the pathogenesis of MB and provide a basis for treatment. however, further experimental verification is needed.
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###### The GSE74195 data set was used for a heat map to represent the common 104 DEGs

Red: upregulated; Green: downregulated

###### 

Click here for additional data file.
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